Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | 김소정 | * |
| dc.date.accessioned | 2024-02-06T16:31:12Z | - |
| dc.date.available | 2024-02-06T16:31:12Z | - |
| dc.date.issued | 2024 | * |
| dc.identifier.issn | 0002-9270 | * |
| dc.identifier.other | OAK-34547 | * |
| dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/267030 | - |
| dc.description.abstract | INTRODUCTION: The incidence of postendoscopic retrograde cholangiopancreatography (ERCP) infections is reported to be up to 18% in patients with biliary obstruction. Antibiotic prophylaxis may reduce the risk of infectious complications after ERCP; however, the clinical value of prophylactic antibiotics in ERCP remains controversial. METHODS: We conducted a double-blind, placebo-controlled, randomized trial to investigate whether the use of prophylactic antibiotics would reduce infectious complications after ERCP in patients with biliary obstruction. We randomly assigned patients in a 1:1 ratio to receive either a single dose of 1 g intravenous cefoxitin or normal saline as a placebo 30 minutes before undergoing ERCP. The primary outcome was the incidence of infectious complications after ERCP. RESULTS: We enrolled 378 patients, and 189 patients were assigned to each group. The risk of infectious complications after ERCP was 2.8% (5 of 176 patients) in the antibiotic prophylaxis group and 9.8% (17 of 173 patients) in the placebo group (risk ratio, 0.29; 95% confidence interval [CI], 0.11–0.74, P 5 0.0073). The incidence rates of bacteremia were 2.3% (4 of 176 patients) and 6.4% (11 of 173 patients), respectively (risk ratio, 0.36; 95% CI, 0.12–1.04; P 5 0.0599). The incidence rate of cholangitis was 1.7% (3 of 176 patients) in the antibiotic prophylaxis group and 6.4% (11 of 173 patients) in the placebo group (risk ratio, 0.27; 95% CI, 0.08–0.87; P 5 0.0267). DISCUSSION: Antibiotic prophylaxis before ERCP in patients with biliary obstruction resulted in a significantly lower risk of infectious complications, especially cholangitis, than placebo (ClinicalTrials.gov trial number NCT02958059). Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology. | * |
| dc.language | English | * |
| dc.publisher | Wolters Kluwer Health | * |
| dc.subject | endoscopic retrograde cholangiopancreatography (ERCP) | * |
| dc.subject | post-ERCP bacteremia | * |
| dc.subject | post-ERCP cholangitis | * |
| dc.subject | post-ERCP complication | * |
| dc.subject | prophylactic antibiotics | * |
| dc.title | Randomized Trial of Prophylactic Antibiotics for Endoscopic Retrograde Cholangiopancreatography in Patients With Biliary Obstruction | * |
| dc.type | Article | * |
| dc.relation.issue | 1 | * |
| dc.relation.volume | 119 | * |
| dc.relation.index | SCIE | * |
| dc.relation.index | SCOPUS | * |
| dc.relation.startpage | 183 | * |
| dc.relation.lastpage | 190 | * |
| dc.relation.journaltitle | American Journal of Gastroenterology | * |
| dc.identifier.doi | 10.14309/ajg.0000000000002495 | * |
| dc.identifier.wosid | WOS:001136575600030 | * |
| dc.identifier.scopusid | 2-s2.0-85181585161 | * |
| dc.author.google | Leem | * |
| dc.author.google | Galam | * |
| dc.author.google | Sung | * |
| dc.author.google | Min Je | * |
| dc.author.google | Park | * |
| dc.author.google | Ji Hoon | * |
| dc.author.google | Kim | * |
| dc.author.google | So Jeong | * |
| dc.author.google | Jo | * |
| dc.author.google | Jung Hyun | * |
| dc.author.google | Lee | * |
| dc.author.google | Hee Seung | * |
| dc.author.google | Ku | * |
| dc.author.google | Nam Su | * |
| dc.author.google | Jeong Youp | * |
| dc.author.google | Bang | * |
| dc.author.google | Seungmin | * |
| dc.author.google | Seung Woo | * |
| dc.author.google | Song | * |
| dc.author.google | Si Young | * |
| dc.author.google | Chung | * |
| dc.author.google | Moon Jae | * |
| dc.contributor.scopusid | 김소정(57216220912;58607872900) | * |
| dc.date.modifydate | 20260604102756 | * |